Validations Queue
49,835 candidate doc → node links pending adjudication. Each was auto-generated by cosine similarity ≥ 0.55 between document and prediction embeddings (bge-base-en-v1.5, 768-dim). Showing page 5 of 12, 200 rows by similarity. Adjudicating updates doc_node_links.reviewed=true with the chosen polarity, writes per-link rows to audit_log, and removes the row from this queue. Phase 4 inference will use confirmed corroborates/contradicts links as Bayesian evidence.
Pending (total)
49,835
Reviewed
13
Filtered
2,297
page 5 / 12
Showing on page
200
Filters
URL params control source + min-similarity threshold
Bulk auto-confirm by similarity threshold
Confirm or label (corroborates / contradicts) all unreviewed links above a similarity threshold in one transaction. Each affected row writes a per-link audit_log entry. Capped at 1,000 links per call. Use Preview first.
Source0 selected · 0 visible
Bulk action
| Sim | Doc | Source | Pred | Domain | Prior | |
|---|---|---|---|---|---|---|
| 0.60 | FDA ANDA207110: BOSENTAN (BOSENTAN) — WATSON LABS INC | fda 2026-04-14 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.60 | FDA BLA761298: PAVBLU (AFLIBERCEPT-AYYH) — AMGEN INC | fda 2026-04-28 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.60 | FDA ANDA211536: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — CIPLA LTD | fda 2026-04-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA ANDA211479: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — MSN | fda 2026-04-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA ANDA210480: LENALIDOMIDE (LENALIDOMIDE) — ALVOGEN | fda 2026-04-27 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.60 | FDA BLA761467: KEYTRUDA QLEX (PEMBROLIZUMAB) — MERCK SHARP DOHME | fda 2026-05-12 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA NDA215430: AUVELITY (BUPROPION HYDROCHLORIDE) — AXSOME | fda 2026-04-30 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.60 | FDA ANDA216327: DILTIAZEM HYDROCHLORIDE (DILTIAZEM HYDROCHLORIDE) — SCIEGEN PHARMS | fda 2026-04-10 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA211582: DAPAGLIFLOZIN (DAPAGLIFLOZIN) — ZYDUS PHARMS | fda 2026-04-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA ANDA060469: TETRACYCLINE HYDROCHLORIDE (TETRACYCLINE HYDROCHLORIDE) — IMPAX LABS | fda 2026-04-17 | 245_009 Breaking plastic-degradation technology could become a supplement that breaks microplastics in the gut before absorption Peter Diamandis | Biotech/Longevity | 45% | |
| 0.60 | FDA ANDA201446: FALLBACK SOLO (LEVONORGESTREL) — LUPIN | fda 2026-05-01 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.60 | FDA BLA761195: VYVGART (EFGARTIGIMOD ALFA) — ARGENX BV | fda 2026-05-08 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.60 | FDA BLA761070: FASENRA (BENRALIZUMAB) — ASTRAZENECA AB | fda 2026-05-13 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.60 | FDA ANDA204994: LACOSAMIDE (LACOSAMIDE) — AUROBINDO PHARMA LTD | fda 2026-05-22 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA BLA761449: TYENNE (TOCILIZUMAB-AAZG) — FRESENIUS KABI USA | fda 2026-05-20 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA ANDA207812: METHOTREXATE SODIUM (METHOTREXATE SODIUM) — ZYDUS PHARMS | fda 2026-05-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA NDA219878: BAXFENDY (BAXDROSTAT) — ASTRAZENECA AB | fda 2026-05-15 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA NDA219943: KOSELUGO (SELUMETINIB) — ASTRAZENECA | fda 2026-05-26 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.60 | FDA ANDA220437: TIVOZANIB (TIVOZANIB) — SANDOZ INC | fda 2026-05-14 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA NDA220711: BEQALZI (SONROTOCLAX) — BEONE MEDICINES USA | fda 2026-05-13 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA ANDA081235: METHOTREXATE SODIUM (METHOTREXATE SODIUM) — MYLAN | fda 2026-05-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA BLA761069: IMFINZI (DURVALUMAB) — ASTRAZENECA UK LTD | fda 2026-05-28 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.60 | FDA ANDA218407: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — SUN PHARM INDS INC | fda 2026-06-03 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.60 | FDA ANDA219288: CYCLOSPORINE (CYCLOSPORINE) — JIANGSU ANBISON | fda 2026-06-01 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA090124: ALENDRONATE SODIUM (ALENDRONATE SODIUM) — AUROBINDO PHARMA | fda 2026-04-15 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA BLA761235: VABYSMO (FARICIMAB-SVOA) — GENENTECH INC | fda 2026-04-09 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA ANDA211846: LENALIDOMIDE (LENALIDOMIDE) — SUN PHARM | fda 2026-04-27 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.60 | FDA ANDA205806: BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (BUPRENORPHINE HYDROCHLORIDE) — DR REDDYS LABS SA | fda 2026-04-15 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA NDA219008: LAZCLUZE (LAZERTINIB MESYLATE) — JANSSEN BIOTECH | fda 2026-04-30 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA ANDA212336: ANDA212336 ((unspecified)) — DR REDDYS LABS LTD | fda 2026-05-07 | CMQ_009 Altman's claim of doctor-level AI diagnostic capability within 2-3 years is 'pure nonsense' — fails to account for medical communication, diagnostic uncertainty, and ethical complexity. Demis Hassabis | AI | 60% | |
| 0.60 | FDA NDA203923: SODIUM THIOSULFATE (SODIUM THIOSULFATE) — HOPE PHARMS | fda 2026-05-07 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA NDA212576: INQOVI (CEDAZURIDINE) — TAIHO ONCOLOGY | fda 2026-05-13 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.60 | FDA ANDA210215: AMANTADINE HYDROCHLORIDE (AMANTADINE HYDROCHLORIDE) — POM PHARMA | fda 2026-05-13 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA ANDA211255: LINACLOTIDE (LINACLOTIDE) — ACTAVIS LABS FL INC | fda 2026-05-19 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA NDA218197: TRUQAP (CAPIVASERTIB) — ASTRAZENECA | fda 2026-05-27 | 248_030 FDA will be first government agency forced to get out of the way; government must accelerate regulation speed thousands of times. Dave Blundin | Geopolitics | 50% | |
| 0.60 | FDA NDA214018: NULIBRY (FOSDENOPTERIN HYDROBROMIDE) — SENTYNL THERAPS INC | fda 2026-05-26 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA BLA761309: COLUMVI (GLOFITAMAB-GXBM) — GENENTECH INC | fda 2026-05-28 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.59 | FDA ANDA207037: OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — ALKEM LABS LTD | fda 2026-04-23 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA NDA021038: PRECEDEX (DEXMEDETOMIDINE HYDROCHLORIDE) — HOSPIRA | fda 2026-05-01 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA BLA125409: PERJETA (PERTUZUMAB) — GENENTECH | fda 2026-04-23 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA210456: MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ASCORBIC ACID) — APOTEX | fda 2026-04-21 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA NDA214120: ONUREG (AZACITIDINE) — BRISTOL | fda 2026-04-09 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.59 | FDA NDA021977: VYVANSE (LISDEXAMFETAMINE DIMESYLATE) — TAKEDA PHARMS USA | fda 2026-04-23 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA NDA215430: AUVELITY (BUPROPION HYDROCHLORIDE) — AXSOME | fda 2026-04-30 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA214618: LENALIDOMIDE (LENALIDOMIDE) — CIPLA | fda 2026-04-27 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA075710: ALENDRONATE SODIUM (ALENDRONATE SODIUM) — IMPAX LABS INC | fda 2026-04-23 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA220421: ANDA220421 ((unspecified)) — HETERO LABS LIMITED, VEMAGAL | fda 2026-05-01 | AI_037 EU AI Act compliance will become a first-class enterprise priority — Anthropic among first frontier labs positioning proactive regulatory governance as a competitive differentiator against hyperscaler peers. Daniella Amodei | Geopolitics | 60% | |
| 0.59 | FDA NDA212576: INQOVI (CEDAZURIDINE) — TAIHO ONCOLOGY | fda 2026-05-13 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.59 | FDA ANDA209224: LACOSAMIDE (LACOSAMIDE) — AUROBINDO PHARMA LTD | fda 2026-05-22 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA200542: LORAZEPAM (LORAZEPAM) — RISING | fda 2026-05-15 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA220747: FINERENONE (FINERENONE) — MACLEODS PHARMACEUTICALS LTD | fda 2026-05-14 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA NDA220442: NDA220442 ((unspecified)) — SHIONOGI INC | fda 2026-05-29 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA NDA201848: HEPZATO (MELPHALAN HYDROCHLORIDE) — DELCATH SYSTEMS INC | fda 2026-05-28 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA NDA210655: PERSERIS KIT (RISPERIDONE) — INDIVIOR | fda 2026-04-30 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA211489: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN, METFORMIN HYDROCHLORIDE) — AUROBINDO PHARMA | fda 2026-04-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA219013: ATROPINE SULFATE (ATROPINE SULFATE) — EDENBRIDGE PHARMS | fda 2026-04-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA211545: DAPAGLIFLOZIN (DAPAGLIFLOZIN) — ALKEM LABS LTD | fda 2026-04-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA NDA216718: SKYCLARYS (OMAVELOXOLONE) — BIOGEN US | fda 2026-04-07 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA211560: DAPAGLIFLOZIN (DAPAGLIFLOZIN) — ALEMBIC | fda 2026-04-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA075388: BUSPIRONE HYDROCHLORIDE (BUSPIRONE HYDROCHLORIDE) — OXFORD PHARMS | fda 2026-04-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA218840: CALCIUM GLUCONATE (CALCIUM GLUCONATE) — CAPLIN | fda 2026-05-04 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA NDA019726: ZOLADEX (GOSERELIN ACETATE) — TERSERA | fda 2026-05-06 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA203103: PROPRANOLOL HYDROCHLORIDE (PROPRANOLOL HYDROCHLORIDE) — IPCA LABS LTD | fda 2026-05-01 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA BLA761170: PHESGO (PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF) — GENENTECH INC | fda 2026-05-18 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA NDA207947: UPTRAVI (SELEXIPAG) — ACTELION | fda 2026-05-23 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA211020: BUPROPION HYDROCHLORIDE (BUPROPION HYDROCHLORIDE) — GRAVITI PHARMS | fda 2026-05-29 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA208539: TICAGRELOR (TICAGRELOR) — MICRO LABS | fda 2026-04-27 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.59 | FDA ANDA079099: LAMOTRIGINE (LAMOTRIGINE) — GLENMARK PHARMS LTD | fda 2026-04-17 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.59 | FDA ANDA091427: PAROXETINE HYDROCHLORIDE (PAROXETINE HYDROCHLORIDE) — AUROBINDO PHARMA USA | fda 2026-04-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA079162: TOPIRAMATE (TOPIRAMATE) — INVAGEN PHARMS | fda 2026-04-24 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA078257: ONDANSETRON HYDROCHLORIDE (ONDANSETRON HYDROCHLORIDE) — ONESOURCE SPECIALTY | fda 2026-04-15 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA BLA761235: VABYSMO (FARICIMAB-SVOA) — GENENTECH INC | fda 2026-04-09 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA NDA021880: REVLIMID (LENALIDOMIDE) — BRISTOL MYERS SQUIBB | fda 2026-04-27 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.59 | FDA ANDA220493: BUPIVACAINE HYDROCHLORIDE (BUPIVACAINE HYDROCHLORIDE) — ANTHEA PHARMA | fda 2026-04-22 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA210480: LENALIDOMIDE (LENALIDOMIDE) — ALVOGEN | fda 2026-04-27 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.59 | FDA ANDA091655: ESCITALOPRAM OXALATE (ESCITALOPRAM OXALATE) — MICRO LABS | fda 2026-04-22 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA216992: DEFLAZACORT (DEFLAZACORT) — UPSHER SMITH LABS | fda 2026-04-09 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA220328: FLUVOXAMINE MALEATE (FLUVOXAMINE MALEATE) — APPCO | fda 2026-04-30 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA204982: PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE (PHENTERMINE HYDROCHLORIDE) — ACTAVIS LABS FL INC | fda 2026-05-01 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA218364: LEVETIRACETAM IN SODIUM CHLORIDE (LEVETIRACETAM) — MYLAN LABS LTD | fda 2026-05-08 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA076228: RISPERIDONE (RISPERIDONE) — HERITAGE PHARMA AVET | fda 2026-05-07 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA BLA761070: FASENRA (BENRALIZUMAB) — ASTRAZENECA AB | fda 2026-05-13 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA BLA761452: IMMGOLIS (GOLIMUMAB-SLDI) — ACCORD BIOPHARMA INC. | fda 2026-05-15 | FUT_019 Global market rapidly accelerates bio-industrial circumvention of fractured supply chains 2026-2031: combination of Webb agentic LAMs overseeing vast bio-reactors powered by sub-cent-per-kWh solar energy creates highly-localized completely-autonomous i... Multi-Forecaster Synthesis | Biotech/Longevity | 31% | |
| 0.59 | FDA NDA220711: BEQALZI (SONROTOCLAX) — BEONE MEDICINES USA | fda 2026-05-13 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA NDA219423: WIDAPLIK (AMLODIPINE BESYLATE) — AZURITY | fda 2026-05-28 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA NDA217379: NDA217379 ((unspecified)) — FLEX PHARMA, LLC | fda 2026-05-29 | 248_030 FDA will be first government agency forced to get out of the way; government must accelerate regulation speed thousands of times. Dave Blundin | Geopolitics | 50% | |
| 0.59 | FDA BLA761309: COLUMVI (GLOFITAMAB-GXBM) — GENENTECH INC | fda 2026-05-28 | IND_012 NVIDIA BioNeMo platform + Evo 2 model fundamentally compresses a century of biology into a decade — Evo 2 achieves 90% accuracy in BRCA1 predictions; AI models will seamlessly transition generated biological designs into practical, synthesized clinical... Jensen Huang | Biotech/Longevity | 68% | |
| 0.59 | FDA ANDA217281: LENALIDOMIDE (LENALIDOMIDE) — NOVUGEN | fda 2026-04-27 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.59 | FDA ANDA212414: LENALIDOMIDE (LENALIDOMIDE) — HETERO LABS LTD V | fda 2026-04-27 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA NDA219293: DANZITEN (NILOTINIB TARTRATE) — AZURITY | fda 2026-04-14 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA220264: VERICIGUAT (VERICIGUAT) — CHANGZHOU PHARMACEUTICAL FACTORY | fda 2026-04-08 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA215759: LENALIDOMIDE (LENALIDOMIDE) — BIOCON PHARMA | fda 2026-04-27 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA211559: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — MACLEODS PHARMS LTD | fda 2026-04-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA211579: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — LUPIN | fda 2026-04-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA NDA217180: JAKAFI XR (RUXOLITINIB PHOSPHATE) — INCYTE CORPORATION | fda 2026-05-01 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.59 | FDA BLA761349: COSENTYX (SECUKINUMAB) — NOVARTIS PHARMS CORP | fda 2026-04-17 | TK13 Biotech/Synbio Safety Event | — | 15% | |
| 0.59 | FDA ANDA212336: ANDA212336 ((unspecified)) — DR REDDYS LABS LTD | fda 2026-05-07 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA216537: CARBIDOPA AND LEVODOPA (CARBIDOPA) — AUROBINDO PHARMA LTD | fda 2026-05-08 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA BLA761449: TYENNE (TOCILIZUMAB-AAZG) — FRESENIUS KABI USA | fda 2026-05-20 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA211026: MACITENTAN (MACITENTAN) — SEASONS BIOTECH | fda 2026-05-19 | INF_039 Consumer-facing AI hardware shortages will worsen: high-Unified-Memory Apple Mac Studio lead times now range 6 days to 6 weeks (up to ~54 days) because data centers are absorbing the world's HBM and memory supply — DRAM market transitioning to hourly v... Alex Finn | Consumer | 77% | |
| 0.59 | FDA ANDA217758: AMMONIUM LACTATE (AMMONIUM LACTATE) — ZYDUS LIFESCIENCES | fda 2026-05-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA NDA022561: MAVENCLAD (CLADRIBINE) — EMD SERONO INC | fda 2026-05-14 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA BLA022472: AFREZZA (INSULIN RECOMBINANT HUMAN) — MANNKIND | fda 2026-05-29 | 245_027 Colossal DNA synthesis delivery will reach 20x the largest prior delivery by end of 2026 Ben Lamm | Biotech/Longevity | 41% | |
| 0.59 | FDA BLA761069: IMFINZI (DURVALUMAB) — ASTRAZENECA UK LTD | fda 2026-05-28 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.59 | FDA ANDA070311: DIAZEPAM (DIAZEPAM) — HIKMA | fda 2026-06-01 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA217281: LENALIDOMIDE (LENALIDOMIDE) — NOVUGEN | fda 2026-04-27 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA212773: IMATINIB MESYLATE (IMATINIB MESYLATE) — EUGIA PHARMA | fda 2026-04-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA078582: LEVETIRACETAM (LEVETIRACETAM) — STRIDES PHARMA | fda 2026-04-21 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.59 | FDA ANDA215243: RAMELTEON (RAMELTEON) — MICRO LABS | fda 2026-04-15 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.59 | FDA NDA020310: NIZORAL ANTI-DANDRUFF (KETOCONAZOLE) — KRAMER | fda 2026-04-30 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA BLA761451: SAPHNELO (ANIFROLIMAB-FNIA) — ASTRAZENECA AB | fda 2026-04-24 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.59 | FDA ANDA090348: ZIPRASIDONE HYDROCHLORIDE (ZIPRASIDONE HYDROCHLORIDE) — CHARTWELL RX | fda 2026-04-24 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA074544: LEUCOVORIN CALCIUM (LEUCOVORIN CALCIUM) — EPIC PHARMA LLC | fda 2026-05-05 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA075327: LEUCOVORIN CALCIUM (LEUCOVORIN CALCIUM) — ANI PHARMS | fda 2026-05-05 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA BLA761352: BIZENGRI (ZENOCUTUZUMAB-ZBCO) — MERUS N.V. | fda 2026-05-08 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA BLA761304: VYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC) — ARGENX BV | fda 2026-05-08 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.59 | FDA ANDA077615: DIVALPROEX SODIUM (DIVALPROEX SODIUM) — APOTEX | fda 2026-05-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA208433: LINAGLIPTIN (LINAGLIPTIN) — TEVA PHARMS USA | fda 2026-05-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA NDA219622: TRIMBOW (BECLOMETHASONE DIPROPIONATE) — CHIESI | fda 2026-05-14 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA NDA217604: PYRIDOSTIGMINE BROMIDE (PYRIDOSTIGMINE BROMIDE) — AMNEAL | fda 2026-05-12 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA NDA217186: CREXONT (CARBIDOPA) — IMPAX | fda 2026-05-15 | 245_009 Breaking plastic-degradation technology could become a supplement that breaks microplastics in the gut before absorption Peter Diamandis | Biotech/Longevity | 45% | |
| 0.59 | FDA ANDA211417: LEVOTHYROXINE SODIUM (LEVOTHYROXINE SODIUM) — MACLEODS PHARMS LTD | fda 2026-05-15 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA220104: MIRTAZAPINE (MIRTAZAPINE) — MICRO LABS | fda 2026-05-19 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.59 | FDA BLA022472: AFREZZA (INSULIN RECOMBINANT HUMAN) — MANNKIND | fda 2026-05-29 | 245_031 99% of synthetic biology focus will remain on human healthcare; similar tech applies more broadly Ben Lamm | Biotech/Longevity | 41% | |
| 0.59 | FDA NDA050574: SANDIMMUNE (CYCLOSPORINE) — NOVARTIS | fda 2026-05-29 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA NDA209803: STEGLATRO (ERTUGLIFLOZIN) — MSD SUB MERCK | fda 2026-06-03 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA215356: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — AUROBINDO PHARMA LTD | fda 2026-06-03 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA202426: SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (METFORMIN HYDROCHLORIDE) — APOTEX | fda 2026-04-30 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.59 | FDA ANDA204687: VALSARTAN AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — SCIEGEN PHARMS | fda 2026-04-23 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA090124: ALENDRONATE SODIUM (ALENDRONATE SODIUM) — AUROBINDO PHARMA | fda 2026-04-15 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.59 | FDA ANDA214398: LENALIDOMIDE (LENALIDOMIDE) — LUPIN | fda 2026-04-27 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.59 | FDA ANDA220274: SODIUM ACETATE (SODIUM ACETATE) — EXTROVIS | fda 2026-04-17 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA203364: MESNA (MESNA) — RISING | fda 2026-04-09 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.59 | FDA ANDA218441: SITAGLIPTIN (SITAGLIPTIN) — BIOCON PHARMA LTD | fda 2026-05-01 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA NDA209500: CAPLYTA (LUMATEPERONE TOSYLATE) — INTRA-CELLULAR | fda 2026-04-24 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA NDA218316: WEGOVY (SEMAGLUTIDE) — NOVO | fda 2026-05-05 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.59 | FDA ANDA078945: ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE (ONDANSETRON HYDROCHLORIDE) — AVET LIFESCIENCES | fda 2026-05-01 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA NDA022433: BRILINTA (TICAGRELOR) — ASTRAZENECA | fda 2026-05-07 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA NDA016730: DEXTROSE 5% IN PLASTIC CONTAINER (DEXTROSE) — B BRAUN | fda 2026-05-12 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA076228: RISPERIDONE (RISPERIDONE) — HERITAGE PHARMA AVET | fda 2026-05-07 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA220078: VORICONAZOLE (VORICONAZOLE) — ZHEJIANG NOVUS | fda 2026-05-05 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA219189: GALLIUM GA-68 GOZETOTIDE (GALLIUM GA-68 GOZETOTIDE) — IONETIX | fda 2026-05-14 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.59 | FDA BLA103792: HERCEPTIN (TRASTUZUMAB) — GENENTECH | fda 2026-05-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA077615: DIVALPROEX SODIUM (DIVALPROEX SODIUM) — APOTEX | fda 2026-05-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA BLA761106: HERCEPTIN HYLECTA (TRASTUZUMAB AND HYALURONIDASE-OYSK) — GENENTECH INC | fda 2026-05-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA216453: METHOTREXATE SODIUM (METHOTREXATE SODIUM) — ELITE LABS INC | fda 2026-05-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA217552: METHOTREXATE SODIUM (METHOTREXATE SODIUM) — ALEMBIC | fda 2026-05-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA BLA761354: TOFIDENCE (TOCILIZUMAB-BAVI) — BIOGEN MA | fda 2026-05-22 | IND_012 NVIDIA BioNeMo platform + Evo 2 model fundamentally compresses a century of biology into a decade — Evo 2 achieves 90% accuracy in BRCA1 predictions; AI models will seamlessly transition generated biological designs into practical, synthesized clinical... Jensen Huang | Biotech/Longevity | 68% | |
| 0.59 | FDA BLA125166: SOLIRIS (ECULIZUMAB) — ALEXION PHARM | fda 2026-06-01 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA NDA217379: NDA217379 ((unspecified)) — FLEX PHARMA, LLC | fda 2026-05-29 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.59 | FDA ANDA217281: LENALIDOMIDE (LENALIDOMIDE) — NOVUGEN | fda 2026-04-27 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA206252: QUETIAPINE FUMARATE (QUETIAPINE FUMARATE) — ACCORD HLTHCARE | fda 2026-04-22 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA210672: MULTIPLE VITAMINS INJECTION ADULT (ALPHA-TOCOPHEROL ACETATE) — APOTEX | fda 2026-04-09 | 245_009 Breaking plastic-degradation technology could become a supplement that breaks microplastics in the gut before absorption Peter Diamandis | Biotech/Longevity | 45% | |
| 0.59 | FDA NDA021121: CONCERTA (METHYLPHENIDATE HYDROCHLORIDE) — JANSSEN PHARMS | fda 2026-04-10 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA078582: LEVETIRACETAM (LEVETIRACETAM) — STRIDES PHARMA | fda 2026-04-21 | 247_041 AI-powered drugs have 85% phase 1 success vs 52% traditional Peter Diamandis | Biotech/Longevity | 55% | |
| 0.59 | FDA BLA125504: COSENTYX (SECUKINUMAB) — NOVARTIS PHARMS CORP | fda 2026-04-17 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.59 | FDA ANDA220660: ELTROMBOPAG OLAMINE (ELTROMBOPAG OLAMINE) — AIZANT | fda 2026-04-28 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA211182: ANDA211182 ((unspecified)) — HETERO LABS LTD V | fda 2026-04-16 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA NDA020785: THALOMID (THALIDOMIDE) — BRISTOL-MYERS | fda 2026-04-27 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.59 | FDA ANDA217239: TORSEMIDE (TORSEMIDE) — MICRO LABS | fda 2026-05-01 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.59 | FDA ANDA213929: LEUCOVORIN CALCIUM (LEUCOVORIN CALCIUM) — LEADING | fda 2026-05-05 | 245_027 Colossal DNA synthesis delivery will reach 20x the largest prior delivery by end of 2026 Ben Lamm | Biotech/Longevity | 41% | |
| 0.59 | FDA NDA212306: XPOVIO (SELINEXOR) — KARYOPHARM THERAPS | fda 2026-04-30 | 235_038 David Sinclair begins partial epigenetic reprogramming trials with Life Biosciences in March 2026. Peter Diamandis | Biotech/Longevity | 74% | |
| 0.59 | FDA NDA021303: ADDERALL XR 10 (AMPHETAMINE ASPARTATE) — TAKEDA PHARMS USA | fda 2026-04-23 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA NDA206829: ZERBAXA (CEFTOLOZANE SULFATE) — CUBIST PHARMS LLC | fda 2026-05-12 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA219189: GALLIUM GA-68 GOZETOTIDE (GALLIUM GA-68 GOZETOTIDE) — IONETIX | fda 2026-05-14 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA219722: L-GLUTAMINE (L-GLUTAMINE) — ANNORA PHARMA | fda 2026-05-26 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.59 | FDA ANDA091404: MEROPENEM (MEROPENEM) — ACS DOBFAR | fda 2026-05-20 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.59 | FDA ANDA212371: EMPAGLIFLOZIN (EMPAGLIFLOZIN) — AUROBINDO PHARMA LIMITED | fda 2026-05-21 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA220299: ISOPROTERENOL HYDROCHLORIDE (ISOPROTERENOL HYDROCHLORIDE) — ASPIRO | fda 2026-05-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA220143: ANDA220143 ((unspecified)) — HETERO LABS LIMITED | fda 2026-05-22 | AI_037 EU AI Act compliance will become a first-class enterprise priority — Anthropic among first frontier labs positioning proactive regulatory governance as a competitive differentiator against hyperscaler peers. Daniella Amodei | Geopolitics | 60% | |
| 0.59 | FDA ANDA081099: METHOTREXATE SODIUM (METHOTREXATE SODIUM) — BARR | fda 2026-05-27 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.59 | FDA ANDA217265: LENALIDOMIDE (LENALIDOMIDE) — QILU | fda 2026-04-27 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.59 | FDA ANDA078244: ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE (ONDANSETRON HYDROCHLORIDE) — ONESOURCE SPECIALTY | fda 2026-04-15 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.59 | FDA NDA217779: RYTELO (IMETELSTAT SODIUM) — GERON | fda 2026-04-14 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA212414: LENALIDOMIDE (LENALIDOMIDE) — HETERO LABS LTD V | fda 2026-04-27 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.59 | FDA ANDA212414: LENALIDOMIDE (LENALIDOMIDE) — HETERO LABS LTD V | fda 2026-04-27 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA NDA217369: ZURZUVAE (ZURANOLONE) — BIOGEN INC | fda 2026-04-20 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA BLA125504: COSENTYX (SECUKINUMAB) — NOVARTIS PHARMS CORP | fda 2026-04-17 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA214398: LENALIDOMIDE (LENALIDOMIDE) — LUPIN | fda 2026-04-27 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.59 | FDA ANDA211482: DAPAGLIFLOZIN (DAPAGLIFLOZIN) — AJANTA PHARMA LTD | fda 2026-04-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA211156: DAPAGLIFLOZIN (DAPAGLIFLOZIN) — INVENTIA | fda 2026-05-28 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA216213: LENALIDOMIDE (LENALIDOMIDE) — AMNEAL | fda 2026-04-27 | CMQ_009 Altman's claim of doctor-level AI diagnostic capability within 2-3 years is 'pure nonsense' — fails to account for medical communication, diagnostic uncertainty, and ethical complexity. Demis Hassabis | AI | 60% | |
| 0.59 | FDA ANDA217957: LEUPROLIDE ACETATE (LEUPROLIDE ACETATE) — UBI | fda 2026-05-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA211182: ANDA211182 ((unspecified)) — HETERO LABS LTD V | fda 2026-04-16 | CMQ_009 Altman's claim of doctor-level AI diagnostic capability within 2-3 years is 'pure nonsense' — fails to account for medical communication, diagnostic uncertainty, and ethical complexity. Demis Hassabis | AI | 60% | |
| 0.59 | FDA BLA761340: EPYSQLI (ECULIZUMAB-AAGH) — SAMSUNG BIOEPIS CO LTD | fda 2026-04-28 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA214376: MYCOPHENOLATE SODIUM (MYCOPHENOLATE SODIUM) — YICHANG HUMANWELL | fda 2026-05-01 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA BLA761342: TALVEY (TALQUETAMAB-TGVS) — JANSSEN BIOTECH | fda 2026-05-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA200217: LORAZEPAM (LORAZEPAM) — RISING | fda 2026-05-04 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.59 | FDA ANDA210236: POMALIDOMIDE (POMALIDOMIDE) — HETERO LABS LTD V | fda 2026-04-27 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA212336: ANDA212336 ((unspecified)) — DR REDDYS LABS LTD | fda 2026-05-07 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA220421: ANDA220421 ((unspecified)) — HETERO LABS LIMITED, VEMAGAL | fda 2026-05-01 | 248_030 FDA will be first government agency forced to get out of the way; government must accelerate regulation speed thousands of times. Dave Blundin | Geopolitics | 50% | |
| 0.59 | FDA BLA761352: BIZENGRI (ZENOCUTUZUMAB-ZBCO) — MERUS N.V. | fda 2026-05-08 | IND_012 NVIDIA BioNeMo platform + Evo 2 model fundamentally compresses a century of biology into a decade — Evo 2 achieves 90% accuracy in BRCA1 predictions; AI models will seamlessly transition generated biological designs into practical, synthesized clinical... Jensen Huang | Biotech/Longevity | 68% | |
| 0.59 | FDA NDA021732: VANTAS (HISTRELIN ACETATE) — ENDO OPERATIONS | fda 2026-05-06 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA211026: MACITENTAN (MACITENTAN) — SEASONS BIOTECH | fda 2026-05-19 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA076089: CIPROFLOXACIN HYDROCHLORIDE (CIPROFLOXACIN HYDROCHLORIDE) — IVAX SUB TEVA PHARMS | fda 2026-05-19 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA BLA022472: AFREZZA (INSULIN RECOMBINANT HUMAN) — MANNKIND | fda 2026-05-29 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA213829: LEUPROLIDE ACETATE (LEUPROLIDE ACETATE) — SOMERSET THERAPS LLC | fda 2026-05-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA208539: TICAGRELOR (TICAGRELOR) — MICRO LABS | fda 2026-04-27 | AI_031 AGI will be defined by its ability to autonomously formulate novel scientific hypotheses — effectively solving '100 years of biology' in a fraction of the historical time required, via continuous hypothesis-generation and experimental iteration. Demis Hassabis | Biotech/Longevity | 51% | |
| 0.59 | FDA ANDA201452: LENALIDOMIDE (LENALIDOMIDE) — ARROW INTL | fda 2026-04-27 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA219897: PIMOZIDE (PIMOZIDE) — NOVITIUM PHARMA | fda 2026-04-13 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% |